0001843762 false 0001843762 2023-01-11 2023-01-11 0001843762 EQRX:CommonStockParValue0.0001PerShareMember 2023-01-11 2023-01-11 0001843762 EQRX:WarrantsToPurchaseOneShareOfCommonStockAtExercisePriceOf11.50Member 2023-01-11 2023-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

 

FORM 8-K 

 

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 11, 2023  

 

 

 

EQRX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40312   86-1691173
(State or other jurisdiction
of incorporation)  		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

50 Hampshire Street, Cambridge, MA   02139
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 617-315-2255

 

Not Applicable

(Former name or former address, if changed since last report.)  

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on which registered
Common stock, par value $0.0001 per share   EQRX   The Nasdaq Global Market
Warrants to purchase one share of common stock at an exercise price of $11.50   EQRXW   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

Although it has not yet finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2022, EQRx, Inc. (“EQRx”) announced on January 11, 2023, that it expects to report that it had approximately $1.4 billion of cash, cash equivalents and short-term investments as of December 31, 2022.

 

The information contained in this Item 2.02 of this Current Report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of EQRx’s financial condition as of December 31, 2022. The audit of EQRx’s consolidated financial statements for the year ended December 31, 2022 is ongoing and could result in changes to the information set forth above.

 

The information in this Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 7.01 Regulation FD Disclosure.

 

EQRx will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. A copy of EQRx’s presentation slides, which will be referenced during the presentation, is furnished herewith as Exhibit 99.1.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		   Description
99.1   Copy of EQRx, Inc.’s presentation slides (furnished herewith)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 11, 2023   EQRX, INC.
     
     
  By: /s/ Melanie Nallicheri
  Name: Melanie Nallicheri
  Title: President and Chief Executive Officer

 

 

 

EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more EQRx Charts.
EQRx (NASDAQ:EQRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more EQRx Charts.